- Home
- ZYME vs UTL Comparison
ZYME vs UTL Comparison
Compare ZYME & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- UTL
- Stock Information
- Founded
- ZYME 2003
- UTL 1984
- Country
- ZYME United States
- UTL United States
- Employees
- ZYME N/A
- UTL N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- UTL Power Generation
- Sector
- ZYME Health Care
- UTL Utilities
- Exchange
- ZYME Nasdaq
- UTL Nasdaq
- Market Cap
- ZYME 968.5M
- UTL 842.0M
- IPO Year
- ZYME 2017
- UTL N/A
- Fundamental
- Price
- ZYME $12.43
- UTL $48.86
- Analyst Decision
- ZYME Buy
- UTL Hold
- Analyst Count
- ZYME 7
- UTL 1
- Target Price
- ZYME $19.50
- UTL $55.00
- AVG Volume (30 Days)
- ZYME 409.0K
- UTL 71.3K
- Earning Date
- ZYME 08-07-2025
- UTL 08-04-2025
- Dividend Yield
- ZYME N/A
- UTL 3.63%
- EPS Growth
- ZYME N/A
- UTL N/A
- EPS
- ZYME N/A
- UTL 2.91
- Revenue
- ZYME $93,384,000.00
- UTL $493,800,000.00
- Revenue This Year
- ZYME $44.71
- UTL $13.90
- Revenue Next Year
- ZYME $34.57
- UTL $7.89
- P/E Ratio
- ZYME N/A
- UTL $17.07
- Revenue Growth
- ZYME 85.05
- UTL N/A
- 52 Week Low
- ZYME $9.03
- UTL $48.93
- 52 Week High
- ZYME $17.70
- UTL $63.52
- Technical
- Relative Strength Index (RSI)
- ZYME 40.44
- UTL 37.04
- Support Level
- ZYME $12.26
- UTL $48.93
- Resistance Level
- ZYME $13.80
- UTL $52.37
- Average True Range (ATR)
- ZYME 0.62
- UTL 1.04
- MACD
- ZYME -0.21
- UTL -0.15
- Stochastic Oscillator
- ZYME 10.19
- UTL 10.02
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.